<p>Jenscare Scientific Co., Ltd. announced that its independently developed LuX-Valve Plus, a transcatheter tricuspid valve replacement system, has received unconditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for its pivotal clinical trial. This approval allows the company to proceed with the pivotal clinical trial of LuX-Valve Plus in the United States. The device has previously demonstrated positive performance in clinical trials conducted in China, Europe, and other regions. The company intends to advance patient enrollment for the pivotal trial and pursue future commercialization of the product in the U.S. and other global markets. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jenscare Scientific Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260206-12018496), on February 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

LABU

Reuters

Proshares Ultra Nasdaq Biotech

iShares US Medical Devices

Direxion S&P Biotech Bull 3X

Proshares UltraShort Nasdaq Biotech

VanEck Biotech ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Health Equip

Direxion S&P Biotech Bear 3X

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Jenscare Scientific Receives FDA Approval for Pivotal Trial of LuX-Valve Plus